Mumbai, November 13,
2025: Alkem
Laboratories Ltd. today announced its standalone and consolidated financial
results for the second quarter ended September 30, 2025. The Board of Directors
took record of these results at its meeting held in Mumbai today.
Key Financial Metrics
Commenting
on the Q2 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said,
“
Q2 FY26 has been another strong quarter for us, marked by robust growth across
India, the US, and key international markets. We also saw healthy traction in
new product launches across markets. The GST revision is a positive step, and
we adapted swiftly to ensure a seamless transition. Our improved gross margins
and operating leverage have contributed to a stronger EBITDA profile. As we
look ahead, we remain focused on accelerating growth and continue to strengthen
our presence in key markets.”
Key
highlights of Q2 FY26 financial performance
·
Total
Revenue from Operations was ₹40,010 million, with YoY growth of 17.2%.
o India sales were ₹27,660 million,
YoY growth of 12.4%.
o International sales were ₹11,890
million, with YoY growth of 29.5%.
·
Earnings
before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹9,208
million, resulting in an EBITDA margin of 23.0% vs. 22.0% in Q2 FY25. EBITDA grew
by 22.3% YoY.
·
Profit
before tax was ₹8,958 million, YoY growth of 14.8%.
·
Net
Profit (after Minority Interest) was ₹7,651 million, YoY growth of 11.1%.
·
According
to IQVIA (SSA) data, for Q2 FY26:
o In the Acute segment, Alkem became the number one
company in IPM this quarter.
o The Company registered a growth of 6.4% YoY in-line with the Indian Pharmaceutical Market (IPM), which also grew by 6.4%.
Operational
Highlights
Domestic
Business – Q2 FY26 Key Highlights
·
India sales were ₹27,660
million, YoY growth of 12.4%.
·
The contribution
of domestic sales to total sales in Q2 FY26 was 69.9% vs. 72.8% in Q2 FY25.
·
As per IQVIA
(SSA) data, during the
quarter, we have outperformed IPM in six therapies: Anti-infectives grew by
~1.2X, Gastrointestinal ~3.1X, VMN ~2.5X, Pain ~2.3X, Respiratory ~1.5X, and
Derma ~3.1X.
International
Business – Q2 FY26 Key Highlights
·
International
sales were ₹11,890 million, YoY growth of 29.5%.
·
US
sales were ₹7,649 million, YoY growth of 28.0%.
·
US
business sales contributed 19.3% to total sales in Q2 FY26.
·
Non-US
sales were ₹4,241 million, YoY growth of 32.4%.
·
Non-US
business sales contributed 10.7% to total sales in Q2 FY26.
·
During Q2 FY26, for the US market, the Company filed 02
ANDAs, received 01 ANDA tentative approvals and launched 04 products.
·
As
of September 30, 2025, the Company had filed 187 ANDAs, 02 NDAs and 01 BLA with
the USFDA. It has received approvals for 163 ANDAs (including 17 tentative
approvals) and 02 NDAs.
Facility Regulatory Status
.JPG)
0 Comments